Data completeness
1/8 — Limited
PERCORTEN by Novartis is clinical pharmacology: desoxycorticosterone pivalate (docp), like other adrenocorticoid hormones, is thought to act by controlling the rate of synthesis of proteins.
Drug data last refreshed 10h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PERCORTEN (desoxycorticosterone pivalate/DOCP) is a long-acting injectable mineralocorticoid ester used to treat hypoadrenocorticism in animals by replacing deficient aldosterone function. It works by binding to cytoplasmic steroid receptors and entering the nucleus to modulate gene transcription, ultimately increasing renal sodium reabsorption and expanding extracellular fluid volume. The drug prevents life-threatening hypotensive shock and pre-renal azotemia in animals with adrenal insufficiency.
PRE_LAUNCH
Pre-launch stage indicates early team building phase with focus on regulatory, medical affairs, and launch readiness roles; commercial scale and team growth trajectory remain undefined.
Mechanism of Action
CLINICAL PHARMACOLOGY: Desoxycorticosterone pivalate (DOCP), like other adrenocorticoid hormones, is thought to act by controlling the rate of synthesis of proteins. It reacts with receptor proteins in the cytoplasm to form a steroid-receptor complex. This complex moves into the nucleus, where it…
Worked on PERCORTEN at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.